(EN) The invention relates to pyrazolo[1,5-a]pyridine compounds as shown in a general formula (I) which is described in the specification, and a preparation method, a pharmaceutical composition and application thereof. In the formula, R1, R2, R3, R4, R5, X, Y and Z are as defined in the specification. The pyrazol[1,5-a]pyridine compound provided by the invention can effectively inhibit fusion of a wild type RET, a mutant type RET, especially a G810R mutant type RET, and RET fusion of KIF5B-RET, CCDC6-RET and the like, is good in safety, and can be used for treating RET-mediated diseases, such as cancers and irritable bowel syndromes.
(ZH) 本发明涉及下述通式(I)所示的吡唑[1,5‑a]吡啶类化合物、其制备方法、药物组合物及应用,式中R1、R2、R3、R4、R5、X、Y、Z如说明书中所定义。本发明所述吡唑[1,5‑a]吡啶类化合物能够有效抑制野生型RET、突变型RET特别是G810R突变型RET、以及KIF5B‑RET和CCDC6‑RET等RET融合,且安全性好,可用于治疗由RET介导的疾病,例如癌症和肠易激综合征。